Is It Time to Implement Adjuvant Targeted Therapy in EGFR-Mutant Non–Small-Cell Lung Cancer?

مواد مشابهة

• Adjuvant EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: still an investigational approach
  بواسطة: Jassem, Jacek
  منشور في: (2019)
• Adjuvant TKI therapy in resected EGFR-mutant non-small-cell lung cancer—ready for prime time?
  بواسطة: Arulananda, Surein, وآخرون
  منشور في: (2020)
• Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough?
  بواسطة: Lemmon, Christopher, وآخرون
  منشور في: (2020)
• Neoadjuvant vs. adjuvant chemotherapy in locally advanced non-small cell lung cancer—is timing everything?
  بواسطة: Subramanian, Melanie P., وآخرون
  منشور في: (2019)
• Optimizing adjuvant therapy in EGFR-mutated non-small cell lung cancer
  بواسطة: Shepherd, Annemarie F., وآخرون
  منشور في: (2020)